NCT01536067View on ClinicalTrials.gov

Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

PHASE2TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

April 30, 2014

Conditions

Waldenström Macroglobulinemia

Interventions

BIOLOGICAL

ofatumumab

Given IV

DRUG

bortezomib

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

10065

Weill Cornell Medical College, New York

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

GlaxoSmithKline

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT01536067 - Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia | Biotech Hunter | Biotech Hunter